153 results on '"Tsalikian E"'
Search Results
2. Persistently High Glucose Levels in Young Children with Type 1 Diabetes (T1D)
- Author
-
Tansey, M., Beck, R., Ruedy, K., Tamborlane, W., Cheng, P., Kollman, C., Fox, L., Weinzimer, S., Mauras, N., White, N. H., and Tsalikian, E.
- Subjects
Blood Glucose ,Male ,Diabetes Mellitus, Type 1 ,Blood Glucose Self-Monitoring ,Child, Preschool ,Age Factors ,Humans ,Infant ,Female ,Child ,Article ,Circadian Rhythm - Abstract
The aim of the study was to characterize glucose levels and variability in young children with type 1 diabetes (T1D).A total of 144 children of 4-10 yr old diagnosed with T1D prior to age 8 were recruited at five DirecNet centers. Participants used a continuous glucose monitor (CGM) every 3 months during an 18-month study. Among the 144 participants, 135 (mean age 7.0 yr, 47% female) had a minimum of 48 h of CGM data at more than five of seven visits and were included in analyses. CGM metrics for different times of day were analyzed.Mean hemoglobin A1c (HbA1c) at the beginning and end of the study was 7.9% (63 mmol/mol). Fifty percent of participants had glucose levels180 mg/dL (10.0 mmol/L) for12 h/d and250 mg/dL (13.9 mmol/L) for6 h/d. Median time70 mg/dL (3.9 mmol/L) was 66 min/d and60 mg/dL (3.3 mmol/L) was 39 min/d. Mean amplitude of glycemic excursions (MAGE) was lowest overnight (00:00-06:00 hours). The percent of CGM values 71-180 mg/dL (3.9-10.0 mmol/L) and the overall mean glucose correlated with HbA1c at all visits. There were no differences in CGM mean glucose or coefficient of variation between the age groups of 4 and6, 6 and8, and 8 and10.Suboptimal glycemic control is common in young children with T1D as reflected by glucose levels in the hyperglycemic range for much of the day. New approaches to reduce postprandial glycemic excursions and increase time in the normal range for glucose in young children with T1D are critically needed. Glycemic targets in this age range should be revisited.
- Published
- 2014
3. 11 Larger Less Frequent Meals Decrease Hunger in the Pediatric Obese Population
- Author
-
Mehra, R, primary, Tsalikian, E, additional, and Sivitz, W, additional
- Published
- 2006
- Full Text
- View/download PDF
4. Diabetes and fructose metabolism
- Author
-
Gerrits, PM, primary and Tsalikian, E, additional
- Published
- 1993
- Full Text
- View/download PDF
5. Differential effects of hyperglycemia and hyperinsulinemia on leucine rate of appearance in normal humans.
- Author
-
Heiling, V J, primary, Campbell, P J, additional, Gottesman, I S, additional, Tsalikian, E, additional, Beaufrere, B, additional, Gerich, J E, additional, and Haymond, M W, additional
- Published
- 1993
- Full Text
- View/download PDF
6. Achievement of target A1C levels with negligible hypoglycemia and low glucose variability in youth with short-term type 1 diabetes and residual β-cell function.
- Author
-
Sherr J, Tamborlane WV, Xing D, Tsalikian E, Mauras N, Buckingham B, White NH, Arbelaez AM, Beck RW, Kollman C, Ruedy K, Diabetes Research in Children Network (DirecNet) Study Group, Sherr, Jennifer, Tamborlane, William V, Xing, Dongyuan, Tsalikian, Eva, Mauras, Nelly, Buckingham, Bruce, White, Neil H, and Arbelaez, Ana Maria
- Abstract
Objective: To determine exposure to hyper- and hypoglycemia using blinded continuous glucose monitoring (CGM) profiles in youth with type 1 diabetes (T1D) with residual β-cell function during the first year of insulin treatment.Research Design and Methods: Blinded, 3-7 day CGM profiles were obtained in 16 short-term T1D patients (age 8-18 years, T1D duration 6-52 weeks) who had peak C-peptide levels ranging from 0.46 to 1.96 nmol/L during a mixed-meal tolerance test. Results in this short-term group were compared with those in 34 patients with well-controlled, longer-term T1D (duration ≥5 years), matched for age and A1C with the short-term T1D group, and with those in 26 age-matched nondiabetic individuals.Results: Despite matching for A1C, and therefore similar mean sensor glucose levels in the two T1D groups, short-term T1D participants had a lower frequency of hypoglycemia (0.3 vs. 7.6%, P < 0.001), a trend toward less hyperglycemia (17 vs. 32%, P = 0.15), and a greater percentage in the target range (median 77 vs. 60%, P = 0.02). Indeed, the percentage of sensor glucose levels ≤70 mg/dL in the short-term T1D group (0.3%) did not differ from those in the nondiabetic group (1.7%, P = 0.73). The coefficient of variation of sensor glucose levels (an index of glucose variability) was lower in short-term vs. longer-term T1D participants (27 vs. 42%, respectively, P < 0.001).Conclusions: In youth with short-term T1D who retain residual β-cell function, there is negligible exposure to hypoglycemia and lower glucose variability than in youth with well-controlled T1D of longer duration. [ABSTRACT FROM AUTHOR]- Published
- 2012
- Full Text
- View/download PDF
7. Normative salivary cortisol values and responsivity in children.
- Author
-
McCarthy AM, Hanrahan K, Kleiber C, Zimmerman MB, Lutgendorf S, and Tsalikian E
- Abstract
This was a descriptive study on normative salivary cortisol values and responsivity to a hospital clinic visit and an intravenous (IV) procedure in children. The study presented was a subproject of a primary research study that examined parents coaching their children requiring an IV placement in the use of distraction. One measure of child response in the primary study, salivary cortisol, was included to further our understanding of children's physiologic response to stressful and painful stimuli. Salivary cortisol samples were obtained from 384 children aged between 4 and 10 years upon arrival to the clinic and 20 minutes after their IV insertion. Baseline samples were collected at home on a typical day for the children. Data from baseline samples were used to establish normative values between 8:00 a.m. and 3:00 p.m. on a nonprocedural day. Results demonstrate that normative cortisol levels in children follow a pattern similar to the circadian pattern in adults, decreasing from early morning to mid afternoon. Matched samples from control group children were used to evaluate group responsivity. Salivary cortisol levels on the baseline day were lower than those obtained during the day of the procedure and tapered over time as expected (-8.7% +/- 6.7%, p = .431). Cortisol levels on the clinic day increased from baseline and increased further in response to IV placement (15.7% +/- 6.7%, p = .023). A Location x Time interaction was significant (p = .019). Findings demonstrate that salivary cortisol is a useful measure of stress response that can be used to evaluate intervention effectiveness. Copyright © 2009 by Elsevier Inc. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
8. Use of the DirecNet Applied Treatment Algorithm (DATA) for diabetes management with a real-time continuous glucose monitor (the FreeStyle Navigator)
- Author
-
Buckingham B, Xing D, Weinzimer S, Fiallo-Scharer R, Kollman C, Mauras N, Tsalikian E, Tamborlane W, Wysocki T, Ruedy K, Beck R, and Diabetes Research In Children Network (DirecNet) Study Group
- Abstract
BACKGROUND: There are no published guidelines for use of real-time continuous glucose monitoring data by a patient; we therefore developed the DirecNet Applied Treatment Algorithm (DATA). The DATA provides algorithms for making diabetes management decisions using glucose values: (i) in real time which include the direction and rate of change of glucose levels, and (ii) retrospectively based on downloaded sensor data. OBJECTIVE: To evaluate the use and effectiveness of the DATA in children with diabetes using a real-time continuous glucose sensor (the FreeStyle Navigator). SUBJECTS: Thirty children and adolescents (mean +/- standard deviation age = 11.2 +/- 4.1 yr) receiving insulin pump therapy. METHODS: Subjects were instructed on use of the DATA and were asked to download their Navigator weekly to review glucose patterns. An Algorithm Satisfaction Questionnaire was completed at 3, 7, and 13 wk. RESULTS: At 13 wk, all of the subjects and all but one parent thought that the DATA gave good, clear directions for insulin dosing, and thought the guidelines improved their postprandial glucose levels. In responding to alarms, 86% of patients used the DATA at least 50% of the time at 3 wk, and 59% reported doing so at 13 wk. Similar results were seen in using the DATA to adjust premeal bolus doses of insulin. CONCLUSIONS: These results show the feasibility of implementing the DATA when real-time continuous glucose monitoring is initiated and support its use in future clinical trials of real-time continuous glucose monitoring. [ABSTRACT FROM AUTHOR]
- Published
- 2008
9. Clinical methods. Strategies for salivary cortisol collection and analysis in research with children.
- Author
-
Hanrahan K, McCarthy AM, Kleiber C, Lutgendorf S, and Tsalikian E
- Abstract
Salivary cortisol has emerged in pediatric research as an easy-to-collect, relatively inexpensive, biologic marker of stress. Cortisol is highly variable and is responsive to a wide range of factors that should be considered when incorporating this measure into research with children. Strategies for sample collection include: (1) standardizing the time for sample collection, including baseline samples; (2) using consistent collection materials and methods; (3) controlling for certain drinks, foods, medications, and diagnoses; and (4) establishing procedures and protocols. Other strategies for laboratory analyses include: (1) selecting the appropriate assay and laboratory; (2) identifying units of measure and norms; and (3) establishing quality controls. These strategies control extraneous variables and produce reliable and valid salivary cortisol results. Copyright © 2006 by Elsevier Inc. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
10. The effects of aerobic exercise on glucose and counterregulatory hormone concentrations in children with type 1 diabetes.
- Author
-
Tansey MJ, Tsalikian E, Beck RW, Mauras N, Buckingham BA, Weinzimer SA, Janz KF, Kollman C, Xing D, Ruedy KJ, Steffes MW, Borland TM, Singh RJ, Tamborlane WV, The Diabetes Research in Children Network (DirecNet) Study Group, Tansey, Michael J, Tsalikian, Eva, Beck, Roy W, Mauras, Nelly, and Buckingham, Bruce A
- Abstract
Objective: To examine the acute glucose-lowering effects of aerobic exercise in children and adolescents with type 1 diabetes.Research Design and Methods: Fifty children and adolescents with type 1 diabetes (ages 10 to <18 years) were studied during exercise. The 75-min exercise session consisted of four 15-min periods of walking on a treadmill to a target heart rate of 140 bpm and three 5-min rest periods. Blood glucose and plasma glucagon, cortisol, growth hormone, and norepinephrine concentrations were measured before, during, and after exercise.Results: In most subjects (83%), plasma glucose concentration dropped at least 25% from baseline, and 15 (30%) subjects became hypoglycemic (< or = 60 mg/dl) or were treated for low glucose either during or immediately following the exercise session. The incidence of hypoglycemia and/or treatment for low glucose varied significantly by baseline glucose, occurring in 86 vs. 13 vs. 6% of subjects with baseline values <120, 120-180, and >180 mg/dl, respectively (P < 0.001). Exercise-induced increases in growth hormone and norepinephrine concentrations were marginally higher in subjects whose glucose dropped < or = 70 mg/dl. Treatment of hypoglycemia with 15 g of oral glucose resulted in only about a 20-mg/dl rise in glucose concentrations.Conclusions: In youth with type 1 diabetes, prolonged moderate aerobic exercise results in a consistent reduction in plasma glucose and the frequent occurrence of hypoglycemia when preexercise glucose concentrations are <120 mg/dl. Moreover, treatment with 15 g of oral glucose is often insufficient to reliably treat hypoglycemia during exercise in these youngsters. [ABSTRACT FROM AUTHOR]- Published
- 2006
11. Impact of exercise on overnight glycemic control in children with type 1 diabetes mellitus.
- Author
-
Tsalikian E, Mauras N, Beck RW, Tamborlane WV, Janz KF, Chase HP, Wysocki T, Weinzimer SA, Buckingham BA, Kollman C, Xing D, Ruedy KJ, Diabetes Research In Children Network Direcnet Study Group, Tsalikian, Eva, Mauras, Nelly, Beck, Roy W, Tamborlane, William V, Janz, Kathleen F, Chase, H Peter, and Wysocki, Tim
- Abstract
Objective: To examine the effect of exercise on overnight hypoglycemia in children with type 1 diabetes mellitus (T1DM).Study Design: At 5 clinical sites, 50 subjects with T1DM (age 11 to 17 years) were studied in a clinical research center on 2 separate days. One day included an afternoon exercise session on a treadmill. On both days, frequently sampled blood glucose levels were measured at the DirecNet central laboratory. Insulin doses were similar on both days.Results: During exercise, plasma glucose levels fell in almost all subjects; 11 (22%) developed hypoglycemia. Mean glucose level from 10 pm to 6 am was lower on the exercise day than on the sedentary day (131 vs 154 mg/dL; P=.003). Hypoglycemia developed overnight more often on the exercise nights than on the sedentary nights (P=.009), occurring on the exercise night only in 13 (26%), on the sedentary night only in 3 (6%), on both nights in 11 (22%), and on neither night in 23 (46%). Hypoglycemia was unusual on the sedentary night if the pre-bedtime snack glucose level was>130 mg/dL.Conclusions: These findings indicate that overnight hypoglycemia after exercise is common in children with T1DM and support the importance of modifying diabetes management after afternoon exercise to reduce the risk of hypoglycemia. [ABSTRACT FROM AUTHOR]- Published
- 2005
12. Blood Glucose Control and Visual and Auditory Attention in Men with Insulin-dependent Diabetes.
- Author
-
Holmes, C. S., Tsalikian, E., and Yamada, T.
- Published
- 1988
- Full Text
- View/download PDF
13. Insulin resistance in acromegaly: defects in both hepatic and extrahepatic insulin action.
- Author
-
HANSEN, I., TSALIKIAN, E., BEAUFRERE, B., GERICH, J., HAYMOND, M., and RIZZA, R.
- Published
- 1986
- Full Text
- View/download PDF
14. Glucose production and utilization in children with glycogen storage disease type I.
- Author
-
TSALIKIAN, E., SIMMONS, P., GERICH, J. E., HOWARD, C., and HAYMOND, M. W.
- Published
- 1984
- Full Text
- View/download PDF
15. Plasma cyclic nucleotide levels in juvenile-onset diabetes.
- Author
-
Goldberg, Melvin L., Bohannon, Nancy V., Brooks, Robert M., Tsalikian, Eva, Lorenzi, Mara, Forsham, Peter H., Goldberg, M L, Bohannon, N V, Brooks, R M, Tsalikian, E, Lorenzi, M, and Forsham, P H
- Published
- 1977
- Full Text
- View/download PDF
16. The effect of chronic oral antidiabetic therapy on insulin and glucagon responses to a meal.
- Author
-
Tsalikian, Eva, Dunphy, Thomas W., Bohannon, Nancy V., Lorenzi, Mara, Gerich, John E., Forsham, Peter H., Kane, John P., Karam, John H., Tsalikian, E, Dunphy, T W, Bohannon, N V, Lorenzi, M, Gerich, J E, Forsham, P H, Kane, J P, and Karam, J H
- Published
- 1977
- Full Text
- View/download PDF
17. Effects of acute insulin withdrawal and administration on plasma glucagon responses to intravenous arginine in insulin-dependent diabetic subjects.
- Author
-
Gerich, John E., Lorenzi, Mara, Tsalikian, Eva, Bohannon, Nancy V., Schneider, Victor, Karam, John H., Forsham, Peter H., Gerich, J E, Lorenzi, M, Tsalikian, E, Bohannon, N V, Schneider, V, Karam, J H, and Forsham, P H
- Published
- 1976
- Full Text
- View/download PDF
18. Studies on the mechanism of epinephrine-induced hyperglycemia in man. Evidence for participation of pancreatic glucagon secretion.
- Author
-
Gerich, John E., Lorenzi, Mara, Tsalikian, Eva, Karam, John H., Gerich, J E, Lorenzi, M, Tsalikian, E, and Karam, J H
- Published
- 1976
- Full Text
- View/download PDF
19. Discordance of diabetic microangiopathy in identical twins.
- Author
-
Karam, J. H., O'Donnell, J. J., Tsalikian, E., Lorenzi, M., Gerich, J. E., Siperstein, M. D., Forsham, P. H., and Rosenthal, M
- Published
- 1976
- Full Text
- View/download PDF
20. Persistence of individual variations in glycated hemoglobin: analysis of data from the Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Randomized Trial.
- Author
-
Wilson DM, Xing D, Cheng J, Beck RW, Hirsch I, Kollman C, Laffel L, Lawrence JM, Mauras N, Ruedy KJ, Tsalikian E, Wolpert H, Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group, Wilson, Darrell M, Xing, Dongyuan, Cheng, Jing, Beck, Roy W, Hirsch, Irl, Kollman, Craig, and Laffel, Lori
- Abstract
Objective: To determine the individual persistence of the relationship between mean sensor glucose (MG) concentrations and hemoglobin A(1c) (A1C) from the Juvenile Diabetes Research Foundation Continuous Glucose Monitoring (CGM) Randomized Trial.Research Design and Methods: MG was calculated using CGM data for 3 months before A1C measurements at 3, 6, 9, and 12 months for the CGM group and at 9 and 12 months for the control group. An MG-to-A1C ratio was included in analysis for subjects who averaged ≥4 days/week of CGM use.Results: Spearman correlations of the MG-to-A1C ratio between consecutive visits 3 months apart ranged from 0.70 to 0.79. The correlations for children and youth were slightly smaller than those for adults. No meaningful differences were observed by device type or change in A1C.Conclusions: Individual variations in the rate of hemoglobin glycation are persistent and contribute to the inaccuracy in estimating MGs calculated from A1C levels. [ABSTRACT FROM AUTHOR]- Published
- 2011
- Full Text
- View/download PDF
21. Characterization of Somatostatin Specific Binding in Plasma Cell Membranes of Human Placenta
- Author
-
Tsalikian, E, Foley, T P, and Becker, D J
- Abstract
Summary: Somatostatin is a known inhibitor of hormone secretion and of nutrient transport. Because somatostatin-like immunoreactivity has been detected in amniotic fluid and the placenta has both hormone secretory and nutrient transport functions, we investigated the possible existence of somatostatin receptors on placenta cell membranes. Binding of 125I-Tyr1-and125I-Tyr11-somatostatin (5-21%) to solubilized placenta cell membranes was observed. Binding was time-, temperature-, and pH-dependent and occurred maximally with incubation at concentrations of 25 µg of membrane protein. Displacement of binding of 125I-Tyr1and Tyr11somatostatin by cold cyclic and linear somatostatin and somatostatin analogs Ala-5, Ala-8, and Ala-11 was observed. Scatchard analysis of data revealed high capacity of (Ro0.44 mol/µg × 10-12) but low affinity (Kd1.8 M × 10-7) binding sites similar to that reported in other tissues. Binding was not reversible under our experimental conditions. The significance of this low affinity binding of somatostatin to placenta cell membranes remains to be determined.
- Published
- 1984
- Full Text
- View/download PDF
22. Effects of diabetes on learning in children
- Author
-
Mccarthy, A. M., Lindgren, S., Michelle Mengeling, Tsalikian, E., and Engvall, J. C.
23. Juvenile diabetes research foundation continuous glucose monitoring study group. The effect of continuous glucose monitoring in well-controlled type 1 diabetes (Diabetes Care (2009) 32, (1378-1383))
- Author
-
Beck, R. W., Hirsch, I. B., Laffel, L., Tamborlane, W. V., Bode, B. W., Buckingham, B., Chase, H. P., Clemons, R., Fiallo-Scharer, R., Fox, L. A., Gilliam, L. K., Huang, E. S., Kollman, C., Kowalski, A. J., Lawrence, J. M., Lee, J., Nelly Mauras, O Grady, M., Ruedy, K. J., Tansey, M., Tsalikian, E., Weinzimer, S. A., Wilson, D. M., Wolpert, H., Wysocki, T., and Xing, D.
24. Effects of [15N]leucine infused at low rates on leucine metabolism in humans
- Author
-
Tessari, P., primary, Tsalikian, E., additional, Schwenk, W. F., additional, Nissen, S. L., additional, and Haymond, M. W., additional
- Published
- 1985
- Full Text
- View/download PDF
25. Differential Effects ofl-Dopa and Apomorphine on Glucagon Secretion in Man: Evidence Against Central Dopaminergic Stimulation of Glucagon
- Author
-
LORENZI, M., primary, TSALIKIAN, E., additional, BOHANNON, N. V., additional, GERICH, J. E., additional, KARAM, J. H., additional, and FORSHAM, P. H., additional
- Published
- 1977
- Full Text
- View/download PDF
26. Characterization of somatostatin (S), binding to solubilized placental cell membranes
- Author
-
Johnson, L M, primary, Becker, D, additional, and Tsalikian, E, additional
- Published
- 1981
- Full Text
- View/download PDF
27. NORMALIZATION OF FASTING HYPERGLUCAGONEMIA AND EXCESSIVE GLUCAGON RESPONSES TO INTRAVENOUS ARGININE IN HUMAN DIABETES MELLITUS BY PROLONGED INFUSION OF INSULIN
- Author
-
Gerich, J. E., primary, Tsalikian, E., additional, Lorenzi, M., additional, Schneider, V., additional, Bohannon, N. V., additional, Gustafson, G., additional, and Karam, J. H., additional
- Published
- 1975
- Full Text
- View/download PDF
28. Effects of physiologic levels of glucagon and growth hormone on human carbohydrate and lipid metabolism. Studies involving administration of exogenous hormone during suppression of endogenous hormone secretion with somatostatin.
- Author
-
Gerich, J E, primary, Lorenzi, M, additional, Bier, D M, additional, Tsalikian, E, additional, Schneider, V, additional, Karam, J H, additional, and Forsham, P H, additional
- Published
- 1976
- Full Text
- View/download PDF
29. Energy Homeostasis in Hypopituitary Children and Controls
- Author
-
Becker, D, primary, Salas, M, additional, Sobel, D, additional, Tsalikian, E, additional, Daneman, D, additional, and Drash, A, additional
- Published
- 1981
- Full Text
- View/download PDF
30. Recycling of an amino acid label with prolonged isotope infusion: implications for kinetic studies
- Author
-
Schwenk, W. F., primary, Tsalikian, E., additional, Beaufrere, B., additional, and Haymond, M. W., additional
- Published
- 1985
- Full Text
- View/download PDF
31. Thyroid hormones and glycosylated hemoglobin (HbA1) in Juvenile Diabetes Mellitus (JDM)
- Author
-
Foley, T, primary, Becker, D, additional, Postellon, D, additional, Daneman, D, additional, Tsalikian, E, additional, White, C, additional, and Drash, A, additional
- Published
- 1979
- Full Text
- View/download PDF
32. Defective glucose counterregulation after subcutaneous insulin in noninsulin-dependent diabetes mellitus. Paradoxical suppression of glucose utilization and lack of compensatory increase in glucose production, roles of insulin resistance, abnormal neuroendocrine responses, and islet paracrine interactions.
- Author
-
Bolli, G B, primary, Tsalikian, E, additional, Haymond, M W, additional, Cryer, P E, additional, and Gerich, J E, additional
- Published
- 1984
- Full Text
- View/download PDF
33. Increased leucine flux in short-term fasted human subjects: evidence for increased proteolysis
- Author
-
Tsalikian, E., primary, Howard, C., additional, Gerich, J. E., additional, and Haymond, M. W., additional
- Published
- 1984
- Full Text
- View/download PDF
34. LARGER LESS FREQUENT MEALS DECREASE HUNGER IN THE PEDIATRIC OBESE POPULATION
- Author
-
Mehra, R, Tsalikian, E, and Sivitz, W
- Published
- 2006
35. Electroencephalographic changes in diabetic ketosis in children with newly and previously diagnosed insulin-dependent diabetes mellitus
- Author
-
TSALIKIAN, E
- Published
- 1981
- Full Text
- View/download PDF
36. Diabetes Device Downloading: Benefits and Barriers Among Youth With Type 1 Diabetes.
- Author
-
Palmer BA, Soltys K, Zimmerman MB, Norris AW, Tsalikian E, Tansey MJ, and Pinnaro CT
- Subjects
- Child, Humans, Adolescent, Blood Glucose, Blood Glucose Self-Monitoring, Cross-Sectional Studies, Glycated Hemoglobin, Retrospective Studies, Insulin therapeutic use, Insulin, Regular, Human, Diabetes Mellitus, Type 1 drug therapy, Diabetes Mellitus, Type 1 complications, Hypoglycemia chemically induced, Hypoglycemia epidemiology, Hypoglycemia complications
- Abstract
Background: The majority of youth with type 1 diabetes (T1D) fail to meet glycemic targets despite increasing continuous glucose monitoring (CGM) use. We therefore aimed to determine the proportion of caregivers who review recent glycemic trends ("retrospective review") and make ensuant insulin adjustments based on this data ("retroactive insulin adjustments"). We additionally considered that fear of hypoglycemia and frequency of severe hypoglycemia would be associated with performing retrospective review., Methods: We conducted a cross-sectional survey of caregivers of youth with T1D, collecting demographics, diabetes technology usage, patterns of glucose data review/insulin dose self-adjustment, and Hypoglycemia Fear Survey (HFS)., Results: Nineteen percent of eligible caregivers (191/1003) responded. Performing retrospective review was associated with younger child age (12.2 versus 15.4, P = .0001) and CGM use (92% versus 73%, P = .004), but was not associated with a significant improvement in child's HbA1c (7.89 versus 8.04, P = .65). Retrospective reviewers had significantly higher HFS-behavior scores (31.9 versus 27.7, P = .0002), which remained significantly higher when adjusted for child's age and CGM use ( P = .005). Linear regression identified a significant negative association between HbA1c (%) and number of retroactive insulin adjustments (0.24 percent lower mean HbA1c per additional adjustment made, P = .02)., Conclusions: Retrospective glucose data review is associated with improved HbA1c when coupled with data-driven retroactive insulin adjustments. Barriers to data downloading existed even in this cohort of predominantly CGM-using T1D families.
- Published
- 2023
- Full Text
- View/download PDF
37. A Pilot randomized trial to examine effects of a hybrid closed-loop insulin delivery system on neurodevelopmental and cognitive outcomes in adolescents with type 1 diabetes.
- Author
-
Reiss AL, Jo B, Arbelaez AM, Tsalikian E, Buckingham B, Weinzimer SA, Fox LA, Cato A, White NH, Tansey M, Aye T, Tamborlane W, Englert K, Lum J, Mazaika P, Foland-Ross L, Marzelli M, and Mauras N
- Subjects
- Adolescent, Blood Glucose, Child, Cognition, Humans, Hypoglycemic Agents therapeutic use, Insulin therapeutic use, Insulin Infusion Systems, Pilot Projects, Diabetes Mellitus, Type 1 chemically induced, Diabetes Mellitus, Type 1 complications, Diabetes Mellitus, Type 1 drug therapy
- Abstract
Type 1 diabetes (T1D) is associated with lower scores on tests of cognitive and neuropsychological function and alterations in brain structure and function in children. This proof-of-concept pilot study (ClinicalTrials.gov Identifier NCT03428932) examined whether MRI-derived indices of brain development and function and standardized IQ scores in adolescents with T1D could be improved with better diabetes control using a hybrid closed-loop insulin delivery system. Eligibility criteria for participation in the study included age between 14 and 17 years and a diagnosis of T1D before 8 years of age. Randomization to either a hybrid closed-loop or standard diabetes care group was performed after pre-qualification, consent, enrollment, and collection of medical background information. Of 46 participants assessed for eligibility, 44 met criteria and were randomized. Two randomized participants failed to complete baseline assessments and were excluded from final analyses. Participant data were collected across five academic medical centers in the United States. Research staff scoring the cognitive assessments as well as those processing imaging data were blinded to group status though participants and their families were not. Forty-two adolescents, 21 per group, underwent cognitive assessment and multi-modal brain imaging before and after the six month study duration. HbA1c and sensor glucose downloads were obtained quarterly. Primary outcomes included metrics of gray matter (total and regional volumes, cortical surface area and thickness), white matter volume, and fractional anisotropy. Estimated power to detect the predicted treatment effect was 0.83 with two-tailed, α = 0.05. Adolescents in the hybrid closed-loop group showed significantly greater improvement in several primary outcomes indicative of neurotypical development during adolescence compared to the standard care group including cortical surface area, regional gray volumes, and fractional anisotropy. The two groups were not significantly different on total gray and white matter volumes or cortical thickness. The hybrid closed loop group also showed higher Perceptual Reasoning Index IQ scores and functional brain activity more indicative of neurotypical development relative to the standard care group (both secondary outcomes). No adverse effects associated with study participation were observed. These results suggest that alterations to the developing brain in T1D might be preventable or reversible with rigorous glucose control. Long term research in this area is needed., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
38. IL-6 receptor blockade does not slow β cell loss in new-onset type 1 diabetes.
- Author
-
Greenbaum CJ, Serti E, Lambert K, Weiner LJ, Kanaparthi S, Lord S, Gitelman SE, Wilson DM, Gaglia JL, Griffin KJ, Russell WE, Raskin P, Moran A, Willi SM, Tsalikian E, DiMeglio LA, Herold KC, Moore WV, Goland R, Harris M, Craig ME, Schatz DA, Baidal DA, Rodriguez H, Utzschneider KM, Nel HJ, Soppe CL, Boyle KD, Cerosaletti K, Keyes-Elstein L, Long SA, Thomas R, McNamara JG, Buckner JH, and Sanda S
- Subjects
- Adolescent, Child, Diabetes Mellitus, Type 1 pathology, Double-Blind Method, Female, Humans, Male, B-Lymphocyte Subsets metabolism, Diabetes Mellitus, Type 1 genetics, Receptors, Interleukin-6 antagonists & inhibitors
- Abstract
BackgroundIL-6 receptor (IL-6R) signaling drives development of T cell populations important to type 1 diabetes pathogenesis. We evaluated whether blockade of IL-6R with monoclonal antibody tocilizumab would slow loss of residual β cell function in newly diagnosed type 1 diabetes patients.MethodsWe conducted a multicenter, randomized, placebo-controlled, double-blind trial with tocilizumab in new-onset type 1 diabetes. Participants were screened within 100 days of diagnosis. Eligible participants were randomized 2:1 to receive 7 monthly doses of tocilizumab or placebo. The primary outcome was the change from screening in the mean AUC of C-peptide collected during the first 2 hours of a mixed meal tolerance test at week 52 in pediatric participants (ages 6-17 years).ResultsThere was no statistical difference in the primary outcome between tocilizumab and placebo. Immunophenotyping showed reductions in downstream signaling of the IL-6R in T cells but no changes in CD4 memory subsets, Th17 cells, Tregs, or CD4+ T effector cell resistance to Treg suppression. A DC subset decreased during therapy but regressed to baseline once therapy stopped. Tocilizumab was well tolerated.ConclusionTocilizumab reduced T cell IL-6R signaling but did not modulate CD4+ T cell phenotypes or slow loss of residual β cell function in newly diagnosed individuals with type 1 diabetes.Trial RegistrationClinicalTrials.gov NCT02293837.FundingNIH National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and National Institute of Allergy and Infectious Diseases (NIAID) UM1AI109565, UL1TR000004 from NIH/National Center for Research Resources (NCRR) Clinical and Translational Science Award (CTSA), NIH/NIDDK P30DK036836, NIH/NIDDK U01DK103266, NIH/NIDDK U01DK103266, 1UL1TR000064 from NIH/NCRR CTSA, NIH/National Center for Advancing Translational Sciences (NCATS) UL1TR001878, UL1TR002537 from NIH/CTSA; National Health and Medical Research Council Practitioner Fellowship (APP1136735), NIH/NIDDK U01-DK085476, NIH/CTSA UL1-TR002494, Indiana Clinical and Translational Science Institute Award UL1TR002529, Vanderbilt Institute for Clinical and Translational Research UL1TR000445. NIH/NCATS UL1TR003142, NIH/CTSA program UL1-TR002494, Veteran Affairs Administration, and 1R01AI132774.
- Published
- 2021
- Full Text
- View/download PDF
39. Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
- Author
-
Gitelman SE, Bundy BN, Ferrannini E, Lim N, Blanchfield JL, DiMeglio LA, Felner EI, Gaglia JL, Gottlieb PA, Long SA, Mari A, Mirmira RG, Raskin P, Sanda S, Tsalikian E, Wentworth JM, Willi SM, Krischer JP, and Bluestone JA
- Subjects
- Adolescent, Adult, Biomarkers analysis, Blood Glucose analysis, Diabetes Mellitus, Type 1 pathology, Double-Blind Method, Female, Follow-Up Studies, Humans, Male, Middle Aged, Prognosis, Young Adult, Diabetes Mellitus, Type 1 drug therapy, Imatinib Mesylate therapeutic use, Protein Kinase Inhibitors therapeutic use
- Abstract
Background: Type 1 diabetes results from autoimmune-mediated destruction of β cells. The tyrosine kinase inhibitor imatinib might affect relevant immunological and metabolic pathways, and preclinical studies show that it reverses and prevents diabetes. Our aim was to evaluate the safety and efficacy of imatinib in preserving β-cell function in patients with recent-onset type 1 diabetes., Methods: We did a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Patients with recent-onset type 1 diabetes (<100 days from diagnosis), aged 18-45 years, positive for at least one type of diabetes-associated autoantibody, and with a peak stimulated C-peptide of greater than 0·2 nmol L
-1 on a mixed meal tolerance test (MMTT) were enrolled from nine medical centres in the USA (n=8) and Australia (n=1). Participants were randomly assigned (2:1) to receive either 400 mg imatinib mesylate (4 × 100 mg film-coated tablets per day) or matching placebo for 26 weeks via a computer-generated blocked randomisation scheme stratified by centre. Treatment assignments were masked for all participants and study personnel except pharmacists at each clinical site. The primary endpoint was the difference in the area under the curve (AUC) mean for C-peptide response in the first 2 h of an MMTT at 12 months in the imatinib group versus the placebo group, with use of an ANCOVA model adjusting for sex, baseline age, and baseline C-peptide, with further observation up to 24 months. The primary analysis was by intention to treat (ITT). Safety was assessed in all randomly assigned participants. This study is registered with ClinicalTrials.gov, NCT01781975 (completed)., Findings: Patients were screened and enrolled between Feb 12, 2014, and May 19, 2016. 45 patients were assigned to receive imatinib and 22 to receive placebo. After withdrawals, 43 participants in the imatinib group and 21 in the placebo group were included in the primary ITT analysis at 12 months. The study met its primary endpoint: the adjusted mean difference in 2-h C-peptide AUC at 12 months for imatinib versus placebo treatment was 0·095 (90% CI -0·003 to 0·191; p=0·048, one-tailed test). This effect was not sustained out to 24 months. During the 24-month follow-up, 32 (71%) of 45 participants who received imatinib had a grade 2 severity or worse adverse event, compared with 13 (59%) of 22 participants who received placebo. The most common adverse events (grade 2 severity or worse) that differed between the groups were gastrointestinal issues (six [13%] participants in the imatinib group, primarily nausea, and none in the placebo group) and additional laboratory investigations (ten [22%] participants in the imatinib group and two [9%] in the placebo group). Per the trial protocol, 17 (38%) participants in the imatinib group required a temporary modification in drug dosing and six (13%) permanently discontinued imatinib due to adverse events; five (23%) participants in the placebo group had temporary modifications in dosing and none had a permanent discontinuation due to adverse events., Interpretation: A 26-week course of imatinib preserved β-cell function at 12 months in adults with recent-onset type 1 diabetes. Imatinib might offer a novel means to alter the course of type 1 diabetes. Future considerations are defining ideal dose and duration of therapy, safety and efficacy in children, combination use with a complimentary drug, and ability of imatinib to delay or prevent progression to diabetes in an at-risk population; however, careful monitoring for possible toxicities is required., Funding: Juvenile Research Diabetes Foundation., Competing Interests: Declaration of interests SEG has served on advisory boards for Avotres, Provention Bio, and Tolerion, and participated in clinical trials with Caladrius, Intrexon, Janssen, Provention Bio, and Tolerion. JLG has consulted for Vertex Pharmaceuticals and Regeneron Pharmaceuticals, and participated in clinical trials for Avotres, Caladrius, Janssen, and Tolerion. PAG has served on advisory boards for Caladrius, Bristol Myers Squibb, and Lilly, received grant support from Caladrius, Novo Nordisk, and Pfizer, and is co-founder and chief medical officer for ImmunoMolecular Therapeutics. RGM has a patent application for DNA methylation in inflammatory disease. SMW reports serving on advisory boards for Boehringer Ingelheim Pharmaceuticals and Medtronic, and a data and safety monitoring board for the US National Institutes of Health (NIH). All other authors declare no competing interests., (Copyright © 2021 Elsevier Ltd. All rights reserved.)- Published
- 2021
- Full Text
- View/download PDF
40. Impact of Type 1 Diabetes in the Developing Brain in Children: A Longitudinal Study.
- Author
-
Mauras N, Buckingham B, White NH, Tsalikian E, Weinzimer SA, Jo B, Cato A, Fox LA, Aye T, Arbelaez AM, Hershey T, Tansey M, Tamborlane W, Foland-Ross LC, Shen H, Englert K, Mazaika P, Marzelli M, and Reiss AL
- Subjects
- Blood Glucose, Blood Glucose Self-Monitoring, Brain diagnostic imaging, Child, Child, Preschool, Female, Humans, Longitudinal Studies, Magnetic Resonance Imaging, Male, Diabetes Mellitus, Type 1 complications
- Abstract
Objective: To assess whether previously observed brain and cognitive differences between children with type 1 diabetes and control subjects without diabetes persist, worsen, or improve as children grow into puberty and whether differences are associated with hyperglycemia., Research Design and Methods: One hundred forty-four children with type 1 diabetes and 72 age-matched control subjects without diabetes (mean ± SD age at baseline 7.0 ± 1.7 years, 46% female) had unsedated MRI and cognitive testing up to four times over 6.4 ± 0.4 (range 5.3-7.8) years; HbA
1c and continuous glucose monitoring were done quarterly. FreeSurfer-derived brain volumes and cognitive metrics assessed longitudinally were compared between groups using mixed-effects models at 6, 8, 10, and 12 years. Correlations with glycemia were performed., Results: Total brain, gray, and white matter volumes and full-scale and verbal intelligence quotients (IQs) were lower in the diabetes group at 6, 8, 10, and 12 years, with estimated group differences in full-scale IQ of -4.15, -3.81, -3.46, and -3.11, respectively ( P < 0.05), and total brain volume differences of -15,410, -21,159, -25,548, and -28,577 mm3 at 6, 8, 10, and 12 years, respectively ( P < 0.05). Differences at baseline persisted or increased over time, and brain volumes and cognitive scores negatively correlated with a life-long HbA1c index and higher sensor glucose in diabetes., Conclusions: Detectable changes in brain volumes and cognitive scores persist over time in children with early-onset type 1 diabetes followed longitudinally; these differences are associated with metrics of hyperglycemia. Whether these changes can be reversed with scrupulous diabetes control requires further study. These longitudinal data support the hypothesis that the brain is a target of diabetes complications in young children., (© 2021 by the American Diabetes Association.)- Published
- 2021
- Full Text
- View/download PDF
41. Human plasma-derived alpha 1 -proteinase inhibitor in patients with new-onset type 1 diabetes mellitus: A randomized, placebo-controlled proof-of-concept study.
- Author
-
Lagarde WH, Courtney KL, Reiner B, Steinmann K, Tsalikian E, and Willi SM
- Subjects
- Adolescent, Adult, C-Peptide blood, Child, Diabetes Mellitus, Type 1 blood, Drug Administration Schedule, Female, Humans, Infusions, Intravenous, Interleukin-6 blood, Male, Proof of Concept Study, Serine Proteinase Inhibitors pharmacokinetics, Treatment Outcome, Young Adult, alpha 1-Antitrypsin pharmacokinetics, Diabetes Mellitus, Type 1 drug therapy, Serine Proteinase Inhibitors administration & dosage, alpha 1-Antitrypsin administration & dosage
- Abstract
Background: While circulating levels of alpha
1 -proteinase inhibitor (alpha1 -PI) are typically normal, antiprotease activity appears to be compromised in patients with Type 1 diabetes mellitus (T1DM). Because alpha1 -PI [human] (alpha1 -PI[h]) therapy can inhibit pro-inflammatory mediators associated with β-cell destruction and reduced insulin production, it has been proposed for T1DM disease prevention. The aim of this study was to evaluate safety, tolerability, and efficacy of intravenous (IV) alpha1 -PI[h] in preserving C-peptide production in newly diagnosed T1DM patients., Participants: Seventy-six participants (aged 6-35 years) were randomized at 25 centers within 3 months of T1DM diagnosis., Methods: A Phase II, multicenter, partially blinded, placebo-controlled, proof-of-concept study evaluating four dosing regimens of alpha1 -PI[h] (NCT02093221, GTI1302): weekly IV infusions of either 90 or 180 mg/kg, each for either 13 or 26 weeks. Safety and efficacy were monitored over 52 weeks with an efficacy evaluation planned at 104 weeks. The primary efficacy endpoint was change from baseline in the 2-h area-under-the-curve C-peptide level from a mixed-meal tolerance test at 52 weeks. A battery of laboratory tests, including inflammatory biomarkers, constituted exploratory efficacy variables., Results: Infusions were well tolerated with no new safety signals. All groups exhibited highly variable declines in the primary outcome measure at 52 weeks with no statistically significant difference from placebo. Interleukin-6 (IL-6) was reduced from baseline in all alpha1 -PI treatment groups but not the placebo group., Conclusion: Pharmacologic therapy with alpha1 -PI[h] is safe, well tolerated, and able to reduce IL-6 levels; however, due to variability in the efficacy endpoint, its effects on preservation of C-peptide production were inconclusive., (© 2020 The Authors. Pediatric Diabetes published by John Wiley & Sons Ltd.)- Published
- 2021
- Full Text
- View/download PDF
42. Parents' relationship maintenance as a buffer for the stress of their adolescent's type 1 diabetes.
- Author
-
Harrison K, Afifi T, Zamanzadeh N, Davis S, Ersig A, Tsalikian E, and Acevedo Callejas M
- Subjects
- Adolescent, Adult, Female, Humans, Male, Diabetes Mellitus, Type 1 psychology, Family Relations psychology, Parents psychology, Spouses psychology, Stress, Psychological psychology
- Abstract
Having an adolescent with Type 1 diabetes (T1D) can be stressful for the entire family. This study examined the impact of parents' relationship maintenance on their ability to manage the conflict associated with their child's T1D, the parents' physiological health (inflammation), and the relationships within the family. Sixty couples and their adolescent children with T1D participated. The couples engaged in a stressful conversation about their child's T1D in their home, followed by random assignment to a 2-week intervention designed to increase the relationship maintenance in the marriage. Results from the home visit revealed that when husbands and wives received greater maintenance from each other the past month, they perceived less conflict when talking about their adolescent's T1D, which was associated with less relational load and lower levels of C-reactive protein (CRP). For wives, greater relationship maintenance was also directly associated with less relational load and lower CRP levels. In addition, the relationship maintenance received was directly and positively associated with parent-child relationship quality for fathers, but this association was mediated by interparental conflict for mothers. Finally, the 2-week intervention reduced parents' relational load and the number of stressful conversations and improved the mother-adolescent relationship but did not significantly reduce parents' CRP. (PsycInfo Database Record (c) 2020 APA, all rights reserved).
- Published
- 2020
- Full Text
- View/download PDF
43. Altered expression of SIRPγ on the T-cells of relapsing remitting multiple sclerosis and type 1 diabetes patients could potentiate effector responses from T-cells.
- Author
-
Sinha S, Renavikar PS, Crawford MP, Steward-Tharp SM, Brate A, Tsalikian E, Tansey M, Shivapour ET, Cho T, Kamholz J, and Karandikar NJ
- Subjects
- Adult, Alleles, Animals, Autoimmunity, Case-Control Studies, Female, Genotype, Humans, Male, Mice, Middle Aged, Polymorphism, Single Nucleotide, Recurrence, T-Lymphocytes immunology, Young Adult, Antigens, Differentiation genetics, Diabetes Mellitus, Type 1 genetics, Diabetes Mellitus, Type 1 immunology, Gene Expression Regulation, Multiple Sclerosis genetics, Multiple Sclerosis immunology, Receptors, Immunologic genetics, T-Lymphocytes metabolism
- Abstract
Factors regulating self-antigen directed immune-responses in autoimmunity are poorly understood. Signal regulatory protein gamma (SIRPγ) is a human T-cell specific protein with genetic variants associated with type 1 diabetes (T1D). SIRPγ's function in the immune system remains unclear. We show that T1D and relapsing remitting multiple sclerosis (RRMS) subjects have significantly greater frequency of rs2281808 T genetic variant, that correlates with reduced SIRPγ-expression in T-cells. Importantly, reduced SIRPγ-expression in RRMS and T1D subjects was not restricted to T variant, suggesting SIRPγ-expression is also regulated by disease specific factors in autoimmunity. Interestingly, increased frequencies of SIRPγlow T-cells in RRMS and T1D positively correlated with proinflammatory molecules from T-cells. Finally, we show that SIRPγlow T-cells have enhanced pathogenecity in vivo in a GVHD model. These findings suggest that decreased-SIRPγ expression, either determined by genetic variants or through peripherally acquired processes, may have a mechanistic link to autoimmunity through induction of hyperactive T-cells., Competing Interests: The authors have declared that no competing interests exist.
- Published
- 2020
- Full Text
- View/download PDF
44. Executive task-based brain function in children with type 1 diabetes: An observational study.
- Author
-
Foland-Ross LC, Buckingam B, Mauras N, Arbelaez AM, Tamborlane WV, Tsalikian E, Cato A, Tong G, Englert K, Mazaika PK, and Reiss AL
- Subjects
- Adolescent, Child, Diabetes Mellitus, Type 1 blood, Female, Humans, Magnetic Resonance Imaging methods, Male, Neuropsychological Tests, Blood Glucose metabolism, Brain physiopathology, Diabetes Mellitus, Type 1 physiopathology, Executive Function physiology
- Abstract
Background: Optimal glycemic control is particularly difficult to achieve in children and adolescents with type 1 diabetes (T1D), yet the influence of dysglycemia on the developing brain remains poorly understood., Methods and Findings: Using a large multi-site study framework, we investigated activation patterns using functional magnetic resonance imaging (fMRI) in 93 children with T1D (mean age 11.5 ± 1.8 years; 45.2% female) and 57 non-diabetic (control) children (mean age 11.8 ± 1.5 years; 50.9% female) as they performed an executive function paradigm, the go/no-go task. Children underwent scanning and cognitive and clinical assessment at 1 of 5 different sites. Group differences in activation occurring during the contrast of "no-go > go" were examined while controlling for age, sex, and scan site. Results indicated that, despite equivalent task performance between the 2 groups, children with T1D exhibited increased activation in executive control regions (e.g., dorsolateral prefrontal and supramarginal gyri; p = 0.010) and reduced suppression of activation in the posterior node of the default mode network (DMN; p = 0.006). Secondary analyses indicated associations between activation patterns and behavior and clinical disease course. Greater hyperactivation in executive control regions in the T1D group was correlated with improved task performance (as indexed by shorter response times to correct "go" trials; r = -0.36, 95% CI -0.53 to -0.16, p < 0.001) and with better parent-reported measures of executive functioning (r values < -0.29, 95% CIs -0.47 to -0.08, p-values < 0.007). Increased deficits in deactivation of the posterior DMN in the T1D group were correlated with an earlier age of T1D onset (r = -0.22, 95% CI -0.41 to -0.02, p = 0.033). Finally, exploratory analyses indicated that among children with T1D (but not control children), more severe impairments in deactivation of the DMN were associated with greater increases in hyperactivation of executive control regions (T1D: r = 0.284, 95% CI 0.08 to 0.46, p = 0.006; control: r = 0.108, 95% CI -0.16 to 0.36, p = 0.423). A limitation to this study involves glycemic effects on brain function; because blood glucose was not clamped prior to or during scanning, future studies are needed to assess the influence of acute versus chronic dysglycemia on our reported findings. In addition, the mechanisms underlying T1D-associated alterations in activation are unknown., Conclusions: These data indicate that increased recruitment of executive control areas in pediatric T1D may act to offset diabetes-related impairments in the DMN, ultimately facilitating cognitive and behavioral performance levels that are equivalent to that of non-diabetic controls. Future studies that examine whether these patterns change as a function of improved glycemic control are warranted., Competing Interests: We have read the journal's policy and the authors of this manuscript the authors have the following competing interests: BB reports financial and other non-financial support from Dexcom, Medtronic Diabetes, Convatec and Insulet. NM reports non-financial support from Medtronic and LifeScan during the conduct of the study, and financial support from Medtronic, Novo Nordisk and Pico Life Technologies outside the submitted work. KE is a consultant with PicoLife technologies, LLC. WVT reports financial support from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Medtronic, Novo Nordisk and Takeda. There are no other relationships or activities that could appear to have influenced the submitted work.
- Published
- 2019
- Full Text
- View/download PDF
45. Testing the Theory of Resilience and Relational Load (TRRL) in Families with Type I Diabetes.
- Author
-
Afifi T, Granger D, Ersig A, Tsalikian E, Shahnazi A, Davis S, Harrison K, Acevedo Callejas M, and Scranton A
- Subjects
- Adolescent, Adult, Child, Fathers psychology, Female, Humans, Hydrocortisone analysis, Male, Middle Aged, Mothers psychology, Negotiating, Socioeconomic Factors, Counseling organization & administration, Diabetes Mellitus, Type 1 psychology, Parents psychology, Resilience, Psychological, Spouses psychology, Stress, Psychological epidemiology
- Abstract
The theory of resilience and relational load was tested with 60 couples and their adolescent children (ages 11-18) with type I diabetes (T1D). The couples participated in a stress-inducing conversation task in their home, followed by a random assignment to a two-week intervention designed to increase their relationship maintenance. Before the intervention, stronger communal orientation predicted greater maintenance for husbands and wives, but maintenance only reduced T1D stress for wives. The wives' and adolescents' T1D stress were also correlated, but the husbands' T1D stress was not significantly associated with either of them. Better maintenance was associated with less conflict during couples' conversations. Maintenance was also directly associated with less perceived and physiological stress (cortisol) from the conversation. Finally, wives in the intervention reported the most thriving, communal orientation and the least loneliness. The intervention also reduced adolescents' general life stress, but it did not influence their T1D stress or thriving.
- Published
- 2019
- Full Text
- View/download PDF
46. An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes.
- Author
-
Herold KC, Bundy BN, Long SA, Bluestone JA, DiMeglio LA, Dufort MJ, Gitelman SE, Gottlieb PA, Krischer JP, Linsley PS, Marks JB, Moore W, Moran A, Rodriguez H, Russell WE, Schatz D, Skyler JS, Tsalikian E, Wherrett DK, Ziegler AG, and Greenbaum CJ
- Subjects
- Adolescent, Adult, Antibodies, Monoclonal, Humanized adverse effects, Child, Diabetes Mellitus, Type 1 genetics, Diabetes Mellitus, Type 1 immunology, Disease Progression, Double-Blind Method, Exanthema chemically induced, Female, Glucose Tolerance Test, HLA-DR3 Antigen, HLA-DR4 Antigen, Humans, Lymphocyte Count, Lymphopenia chemically induced, Male, Middle Aged, Proportional Hazards Models, T-Lymphocytes immunology, Young Adult, Antibodies, Monoclonal, Humanized therapeutic use, CD3 Complex antagonists & inhibitors, Diabetes Mellitus, Type 1 prevention & control
- Abstract
Background: Type 1 diabetes is a chronic autoimmune disease that leads to destruction of insulin-producing beta cells and dependence on exogenous insulin for survival. Some interventions have delayed the loss of insulin production in patients with type 1 diabetes, but interventions that might affect clinical progression before diagnosis are needed., Methods: We conducted a phase 2, randomized, placebo-controlled, double-blind trial of teplizumab (an Fc receptor-nonbinding anti-CD3 monoclonal antibody) involving relatives of patients with type 1 diabetes who did not have diabetes but were at high risk for development of clinical disease. Patients were randomly assigned to a single 14-day course of teplizumab or placebo, and follow-up for progression to clinical type 1 diabetes was performed with the use of oral glucose-tolerance tests at 6-month intervals., Results: A total of 76 participants (55 [72%] of whom were ≤18 years of age) underwent randomization - 44 to the teplizumab group and 32 to the placebo group. The median time to the diagnosis of type 1 diabetes was 48.4 months in the teplizumab group and 24.4 months in the placebo group; the disease was diagnosed in 19 (43%) of the participants who received teplizumab and in 23 (72%) of those who received placebo. The hazard ratio for the diagnosis of type 1 diabetes (teplizumab vs. placebo) was 0.41 (95% confidence interval, 0.22 to 0.78; P = 0.006 by adjusted Cox proportional-hazards model). The annualized rates of diagnosis of diabetes were 14.9% per year in the teplizumab group and 35.9% per year in the placebo group. There were expected adverse events of rash and transient lymphopenia. KLRG1+TIGIT+CD8+ T cells were more common in the teplizumab group than in the placebo group. Among the participants who were HLA-DR3-negative, HLA-DR4-positive, or anti-zinc transporter 8 antibody-negative, fewer participants in the teplizumab group than in the placebo group had diabetes diagnosed., Conclusions: Teplizumab delayed progression to clinical type 1 diabetes in high-risk participants. (Funded by the National Institutes of Health and others; ClinicalTrials.gov number, NCT01030861.)., (Copyright © 2019 Massachusetts Medical Society.)
- Published
- 2019
- Full Text
- View/download PDF
47. Metformin Improves Peripheral Insulin Sensitivity in Youth With Type 1 Diabetes.
- Author
-
Cree-Green M, Bergman BC, Cengiz E, Fox LA, Hannon TS, Miller K, Nathan B, Pyle L, Kahn D, Tansey M, Tichy E, Tsalikian E, Libman I, and Nadeau KJ
- Subjects
- Adipose Tissue metabolism, Adolescent, Adult, Blood Glucose analysis, Child, Diabetes Mellitus, Type 1 metabolism, Double-Blind Method, Female, Humans, Liver metabolism, Male, Metformin adverse effects, Young Adult, Diabetes Mellitus, Type 1 drug therapy, Hypoglycemic Agents therapeutic use, Insulin Resistance, Metformin therapeutic use
- Abstract
Context: Type 1 diabetes in adolescence is characterized by insulin deficiency and insulin resistance (IR), both thought to increase cardiovascular disease risk. We previously demonstrated that adolescents with type 1 diabetes have adipose, hepatic, and muscle IR, and that metformin lowers daily insulin dose, suggesting improved IR. However, whether metformin improves IR in muscle, hepatic, or adipose tissues in type 1 diabetes was unknown., Objective: Measure peripheral, hepatic, and adipose insulin sensitivity before and after metformin or placebo therapy in youth with obesity with type 1 diabetes., Design: Double-blind, placebo-controlled clinical trial., Setting: Multi-center at eight sites of the T1D Exchange Clinic Network., Participants: A subset of 12- to 19-year-olds with type 1 diabetes (inclusion criteria: body mass index ≥85th percentile, HbA1c 7.5% to 9.9%, insulin dosing ≥0.8 U/kg/d) from a larger trial (NCT02045290) were enrolled., Intervention: Participants were randomized to 3 months of metformin (N = 19) or placebo (N = 18) and underwent a three-phase hyperinsulinemic euglycemic clamp with glucose and glycerol isotope tracers to assess tissue-specific IR before and after treatment., Main Outcome Measures: Peripheral insulin sensitivity, endogenous glucose release, rate of lipolysis., Results: Between-group differences in change in insulin sensitivity favored metformin regarding whole-body IR [change in glucose infusion rate 1.3 (0.1, 2.4) mg/kg/min, P = 0.03] and peripheral IR [change in metabolic clearance rate 0.923 (-0.002, 1.867) dL/kg/min, P = 0.05]. Metformin did not impact insulin suppression of endogenous glucose release (P = 0.12). Adipose IR was not assessable with traditional methods in this highly IR population., Conclusions: Metformin appears to improve whole-body and peripheral IR in youth who are overweight/obese with type 1 diabetes., (Copyright © 2019 Endocrine Society.)
- Published
- 2019
- Full Text
- View/download PDF
48. Risk variants disrupting enhancers of T H 1 and T REG cells in type 1 diabetes.
- Author
-
Gao P, Uzun Y, He B, Salamati SE, Coffey JKM, Tsalikian E, and Tan K
- Subjects
- Child, Preschool, Epigenomics, Female, Genome-Wide Association Study, Humans, Infant, Jurkat Cells, Male, Risk Factors, T-Lymphocytes, Regulatory pathology, Th1 Cells pathology, Diabetes Mellitus, Type 1 genetics, Diabetes Mellitus, Type 1 immunology, Diabetes Mellitus, Type 1 pathology, Enhancer Elements, Genetic, Polymorphism, Single Nucleotide, Retinoic Acid Receptor alpha genetics, Retinoic Acid Receptor alpha immunology, T-Lymphocytes, Regulatory immunology, Th1 Cells immunology, YY1 Transcription Factor genetics, YY1 Transcription Factor immunology
- Abstract
Genome-wide association studies (GWASs) have revealed 59 genomic loci associated with type 1 diabetes (T1D). Functional interpretation of the SNPs located in the noncoding region of these loci remains challenging. We perform epigenomic profiling of two enhancer marks, H3K4me1 and H3K27ac, using primary T
H 1 and TREG cells isolated from healthy and T1D subjects. We uncover a large number of deregulated enhancers and altered transcriptional circuitries in both cell types of T1D patients. We identify four SNPs (rs10772119, rs10772120, rs3176792, rs883868) in linkage disequilibrium (LD) with T1D-associated GWAS lead SNPs that alter enhancer activity and expression of immune genes. Among them, rs10772119 and rs883868 disrupt the binding of retinoic acid receptor α (RARA) and Yin and Yang 1 (YY1), respectively. Loss of binding by YY1 also results in the loss of long-range enhancer-promoter interaction. These findings provide insights into how noncoding variants affect the transcriptomes of two T-cell subtypes that play critical roles in T1D pathogenesis., Competing Interests: The authors declare no conflict of interest., (Copyright © 2019 the Author(s). Published by PNAS.)- Published
- 2019
- Full Text
- View/download PDF
49. Impact of Early Diabetic Ketoacidosis on the Developing Brain.
- Author
-
Aye T, Mazaika PK, Mauras N, Marzelli MJ, Shen H, Hershey T, Cato A, Weinzimer SA, White NH, Tsalikian E, Jo B, and Reiss AL
- Subjects
- Age of Onset, Brain diagnostic imaging, Case-Control Studies, Child, Child, Preschool, Cognition physiology, Cognition Disorders diagnosis, Cognition Disorders epidemiology, Cognition Disorders physiopathology, Diabetes Mellitus, Type 1 epidemiology, Diabetes Mellitus, Type 1 physiopathology, Diabetic Ketoacidosis diagnosis, Diabetic Ketoacidosis epidemiology, Diabetic Ketoacidosis physiopathology, Female, Functional Neuroimaging, Humans, Magnetic Resonance Imaging, Male, Severity of Illness Index, Brain growth & development, Brain physiopathology, Cognition Disorders etiology, Diabetes Mellitus, Type 1 complications, Diabetes Mellitus, Type 1 psychology, Diabetic Ketoacidosis psychology
- Abstract
Objective: This study examined whether a history of diabetic ketoacidosis (DKA) is associated with changes in longitudinal cognitive and brain development in young children with type 1 diabetes., Research Design and Methods: Cognitive and brain imaging data were analyzed from 144 children with type 1 diabetes, ages 4 to <10 years, who participated in an observational study of the Diabetes Research in Children Network (DirecNet). Participants were grouped according to history of DKA severity (none/mild or moderate/severe). Each participant had unsedated MRI scans and cognitive testing at baseline and 18 months., Results: In 48 of 51 subjects, the DKA event occurred at the time of onset, at an average of 2.9 years before study entry. The moderate/severe DKA group gained more total and regional white and gray matter volume over the observed 18 months compared with the none/mild group. When matched by age at time of enrollment and average HbA
1c during the 18-month interval, participants who had a history of moderate/severe DKA compared with none/mild DKA were observed to have significantly lower Full Scale Intelligence Quotient scores and cognitive performance on the Detectability and Commission subtests of the Conners' Continuous Performance Test II and the Dot Locations subtest of the Children's Memory Scale., Conclusions: A single episode of moderate/severe DKA in young children at diagnosis is associated with lower cognitive scores and altered brain growth. Further studies are needed to assess whether earlier diagnosis of type 1 diabetes and prevention of DKA may reduce the long-term effect of ketoacidosis on the developing brain., (© 2018 by the American Diabetes Association.)- Published
- 2019
- Full Text
- View/download PDF
50. Individual glucose responses to prolonged moderate intensity aerobic exercise in adolescents with type 1 diabetes: The higher they start, the harder they fall.
- Author
-
Riddell MC, Zaharieva DP, Tansey M, Tsalikian E, Admon G, Li Z, Kollman C, and Beck RW
- Subjects
- Adolescent, Blood Glucose Self-Monitoring, Child, Cohort Studies, Diabetes Mellitus, Type 1 complications, Diabetes Mellitus, Type 1 drug therapy, Exercise Test, Female, Humans, Hyperglycemia blood, Hyperglycemia complications, Hypoglycemia blood, Individuality, Insulin administration & dosage, Insulin adverse effects, Insulin Infusion Systems, Male, Retrospective Studies, Risk Factors, Blood Glucose metabolism, Diabetes Mellitus, Type 1 blood, Exercise physiology, Hypoglycemia etiology
- Abstract
Objective: To evaluate the pattern of change in blood glucose concentrations and hypoglycemia risk in response to prolonged aerobic exercise in adolescents with type 1 diabetes (T1D) that had a wide range in pre-exercise blood glucose concentrations., Methods: Individual blood glucose responses to prolonged (~60 minutes) moderate-intensity exercise were profiled in 120 youth with T1D., Results: The mean pre-exercise blood glucose concentration was 178 ± 66 mg/dL, ranging from 69 to 396 mg/dL, while the mean change in glucose during exercise was -76 ± 55 mg/dL (mean ± SD), ranging from +83 to -257 mg/dL. Only 4 of 120 youth (3%) had stable glucose levels during exercise (ie, ± ≤10 mg/dL), while 4 (3%) had a rise in glucose >10 mg/dL, and the remaining (93%) had a clinically significant drop (ie, >10 mg/dL). A total of 53 youth (44%) developed hypoglycemia (≤70 mg/dL) during exercise. The change in glucose was negatively correlated with the pre-exercise glucose concentration (R
2 = 0.44, P < 0.001), and tended to be greater in those on multiple daily insulin injections (MDI) vs continuous subcutaneous insulin infusion (CSII) (-98 ± 15 vs -65 ± 7 mg/dL, P = 0.05). No other collected variables appeared to predict the change in glucose including age, weight, height, body mass index, disease duration, daily insulin dose, HbA1c , or sex., Conclusion: Youth with T1D have variable glycemic responses to prolonged aerobic exercise, but this variability is partially explained by their pre-exercise blood glucose levels. When no implementation strategies are in place to limit the drop in glycemia, the incidence of exercise-associated hypoglycemia is ~44% and having a high pre-exercise blood glucose concentration is only marginally protective., (© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.